UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **August 15, 2022**

Dermata Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	**001-40739**	**86-3218736**
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

3525 Del Mar Heights Rd., #322
San Diego, CA 92130
(Address of principal executive offices, including zip code)

(858) 800-2543
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class:	**Trading Symbol**	**Name of Each Exchange on which Registered**
Common Stock, par value $0.0001 per share	DRMA	The Nasdaq Capital Market
Warrants, exercisable for one share of Common Stock	DRMAW	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 2.02. Results of Operations and Financial Condition.

On August 15, 2022, Dermata Therapeutics, Inc. (the "Company") issued a press release disclosing certain information regarding its results of operations for the fiscal period ended June 30, 2022. A copy of the press release is furnished under Item 2.02 as Exhibit 99.1.

The information included in this Item 2.02, and Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed "filed" for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934 as amended (the "Exchange Act"). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act made after the date hereof, the information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 7.01. Regulation FD Disclosure.

See "Item 2.02 Results of Operations and Financial Condition" above.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release, dated August 15, 2022, issued by Dermata Therapeutics, Inc. entitled "Dermata Therapeutics, Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial Results."
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DERMATA THERAPEUTICS, INC.

Dated: August 15, 2022

By: */s/ Gerald T. Proehl*
Gerald T. Proehl
Chief Executive Officer

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

- Dermata completes a $5.0 million private placement financing in April 2022 -

- DMT310 Phase 2 rosacea trial topline results expected in the second half of 2022 -

SAN DIEGO, CA, August 15, 2022 – Dermata Therapeutics, Inc. (Nasdaq: DRMA; DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today highlighted recent corporate progress and reported financial results for the quarter ended June 30, 2022.

"It is a big step for our DTM310 rosacea program to have fully enrolled our Phase 2 study in moderate-to-severe rosacea. If successful, this could be the first once-weekly topical product for the treatment of rosacea and could cause a shift in how this disease is treated," commented Gerry Proehl, Dermata's Chairman, President, and Chief Executive Officer. "We also continue to explore partnering opportunities with botulinum toxin companies to advance our DMT410 program into later stages of development. We believe DMT410's ability to facilitate the intradermal delivery of botulinum toxin via topical applications could provide a more targeted and safer delivery option for hyperhidrosis and aesthetic skin conditions," concluded Mr. Proehl.

Corporate Highlights

- **In April 2022, Dermata successfully closed a $5.0 million private placement.** The Company closed a private placement with a single institutional investor of 898,585 shares of the Company's common stock, pre-funded warrants to purchase up to 2,875,000 shares of common stock (or pre-funded warrants to purchase common stock in lieu thereof) and warrants to purchase up to 3,773,585 shares of common stock, for net proceeds of $4.3 million, after deducting the placement agent's fees and other offering expenses. The private placement was priced at the market under Nasdaq rules.

- **Enrollment completed in DMT310 Phase 2 moderate-to-severe rosacea study.** In June 2022, the Company completed enrollment of a Phase 2 study of once-weekly treatment of DMT310 in moderate-to-severe rosacea. The treatment phase of the study is ongoing.

Anticipated Upcoming Milestones

- **DMT310 Phase 2 results in moderate-to-severe rosacea.** The Company expects to receive topline results in the second half of 2022. The trial is a 12-week, double-blinded, randomized, placebo-controlled study with 180 patients enrolled at 20 clinical sites in the United States. The co-primary endpoints are (i) absolute reduction in inflammatory lesion count and (ii) Investigator Global Assessment ("IGA"), which will be graded on a 5-point scale (0-4). To be considered a responder, a patient needs to have at least a 2-grade reduction and an IGA score of 0 or 1. Upon successful results, the Company will look to request an end of Phase 2 meeting with the FDA.

- **DMT310 Phase 3 program in moderate-to-severe acne**. After an end of Phase 2 meeting with FDA planned for the first half of 2023, the Company intends to initiate the Phase 3 acne program.

Second Quarter 2022 Financial Results

As of June 30, 2022, Dermata had $10.6 million in cash, compared to $10.8 million as of December 31, 2021. Dermata received net proceeds of $4.3 million in April 2022 from a private placement of its securities, which, together with existing cash resources, are expected to fund operations into the third quarter of 2023.

Research and development expenses were $1.6 million for the quarter ended June 30, 2022, compared to $0.9 million for the quarter ended June 30, 2021. The increase in research and development expenses was due to increased clinical trial and non-clinical expenses, as well as increases in personnel-related expenses. Stock-based compensation expense attributable to research and development totaled $0.05 million for the quarter ended June 30, 2022 compared to $0.03 million for the quarter ended June 30, 2021.

General and administrative expenses were $1.1 million for the quarter ended June 30, 2022, compared to $0.5 million for the quarter ended June 30, 2021. The increase in general and administrative expenses was due to insurance and other public company costs, as well as an increase in personnel-related expenses and stock-based compensation expense. Stock-based compensation expense attributable to general and administrative totaled $0.2 million for the quarter ended June 30, 2022 compared to $0.08 million for the quarter ended June 30, 2021.

About Dermata Therapeutics

Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions. The Company's lead product candidate, DMT310, is the first product candidate being developed from its *Spongilla* technology platform. DMT310 is a once-weekly topical product candidate derived from a naturally sourced freshwater sponge with multiple unique mechanisms of action. DMT310 is currently under clinical development for the treatment of acne, rosacea, and psoriasis. The Company's second product candidate, DMT410, uses its *Spongilla* technology as a new method for topical intradermal delivery of botulinum toxin for the treatment of hyperhidrosis and multiple aesthetic skin conditions. Dermata is headquartered in San Diego, California. For more information, please visit http://www.dermatarx.com/.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company's current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but are not limited to, statements related to: expectations with regard to the timing of data events; expectations with regard to the timing and/or results from meetings with regulatory bodies; expectations with regard to any potential partnership opportunities for the Company's product candidates; the Company's expectations with regard to current cash and the amount of time it will fund operations; the success, cost, and timing of its product candidates DMT310 and DMT410 development activities and ongoing and planned clinical trials; and whether the results of DMT310 or DMT410 will lead to future product development. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to Dermata's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

DERMATA THERAPEUTICS, INC.
(Formerly Dermata Therapeutics, LLC)
Balance Sheets

In thousands, except share and per share data	June 30, 2022 (unaudited)	December 31, 2021
Assets		
Cash	$ 10,628	$ 10,799
Prepaid expenses and other current assets	398	825
Total assets	11,026	11,624
Liabilities		
Accounts payable	609	515
Accrued liabilities	757	1,002
Total liabilities	1,366	1,517
Equity	9,660	10,107
Total liabilities and equity	$ 11,026	$ 11,624

DERMATA THERAPEUTICS, INC.
(Formerly Dermata Therapeutics, LLC)
Statements of Operations

	Three Months Ended June 30,		Six Months Ended June 30,	
	2022	2021	2022	2021
In thousands, except share and per share data	(unaudited)	(unaudited)	(unaudited)	(unaudited)
Operating expenses				
Research and development (1)	$ 1,613	$ 867	$ 3,208	$ 1,548
General and administrative (1)	1,118	463	2,308	2,044
Total operating expenses	2,731	1,330	5,516	3,592
Loss from operations	(2,731)	(1,330)	(5,516)	(3,592)
Interest expense, net	-	2	-	45
Net loss	$ (2,731)	$ (1,332)	$ (5,516)	$ (3,637)
Net loss per common share, basic and diluted	$ (0.24)	$ (0.70)	$ (0.56)	$ (1.90)
Weighted average common shares outstanding, basic and diluted	11,194,857	1,911,009	9,781,510	1,911,009
(1) Includes the following stock-based compensation expense				
Research and development	$ 53	$ 30	$ 109	$ 280
General and administrative	$ 208	$ 84	$ 366	$ 994

Investors:
Sean Proehl
Senior Director, Legal and Business Development